We found that the p53 protein over-expression (encoded by TP53) was consistently predictable in six of the eight tested cancers, including renal cell carcinomas, lower-grade brain glioma, and endometrial cancer, with AUCs ranging from 0.672 to 0.835. This evidence concerns the gene TP53 and brain glioma.